Congenital and Acquired Disorders of Macrophages and Histiocytes, An Issue of Hematology/Oncology Clinics of North America

Nancy Berliner

Description

This issue of Hematology/Oncology Clinics of North America is devoted to Congenital and Acquired Disorders of Macrophages and Histiocytes. Guest Editors Nancy Berliner, MD and Barrett Rollins, MD have assembled a group of expert authors to review the following topics: Nosology of Langerhans Cell Histiocytosis (LCH); Cell of Origin of LCH; Genomic Changes in LCH; Clinical Treatment of LCH; Neurodegeneration in LCH; Pathogenesis of Hemophagocytic Lymphohistiocytosis (HLH); Familial HLH; HLH in Adults; Macrophage Activation Syndrome; and Stem Cell Transplant for HLH.

Sujets

• Médecine
• Medical
• Hermatology

Informations

• Publié par: Elsevier
• Date de parution: 07 janvier 2016
• Nombre de lectures: 0
• EAN13: 9780323400893
• Langue: English
• Poids de l'ouvrage: 6 Mo

Extrait

Congenital and Acquired Disorders of Macrophages and Histiocytes
Hematology/Oncology Clinics of North America
Editors
Nancy Berliner, MD
Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Barrett J. Rollins, MD, PhD
Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massuchusetts, USA
Consulting Editors
George P. Canellos
H. Franklin Bunn

Clinics Review Articles

www.hemonc.theclinics.com

October 2015 Volume 29 Number 5
Table of Contents
Cover image
Title page
Copyright
Contributors
Consulting Editors
Editors
Authors
Forthcoming Issues
Forthcoming Issues
Recent Issues
Dedication
Preface. Congenital and Acquired Disorders of Macrophages and Histiocytes
Nosology and Pathology of Langerhans Cell Histiocytosis
Key points
Pathology of the histiocytoses
General histopathology
Histopathology in specific organs
Summary
References
Cell(s) of Origin of Langerhans Cell Histiocytosis
Key points
Introduction to Langerhans cell histiocytosis
Molecular insights into pathogenesis of Langerhans cell histiocytosis
Branches of dendritic cell differentiation
Revisiting the cell of origin in Langerhans cell histiocytosis
Summary/future directions
References
Genomic Alterations in Langerhans Cell Histiocytosis
Key points
Introduction
Mitogen-activated protein kinase pathway activation
Clinical implications
Summary
References
Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis
Key points
Introduction
Biology
Epidemiology
Pathology
Clinical presentation
Sites of involvement
Treatment of Langerhans cell histiocytosis
Treatment of recurrent Langerhans cell histiocytosis
Special considerations
Summary and future directions
References
Strategies for the Prevention of Central Nervous System Complications in Patients with Langerhans Cell Histiocytosis: The Problem of Neurodegenerative Syndrome
Key points
Introduction
Laboratory studies of relevance to central nervous system-Langerhans cell histiocytosis disease
Laboratory and therapeutic studies to prevent and treat neurodegeneration-central nervous system-Langerhans cell histiocytosis disease
Summary and future directions
References
Pathogenesis of Hemophagocytic Lymphohistiocytosis
Key points
Introduction
Disease description
Genetics of hemophagocytic lmphohistiocytosis
Secondary hemophagocytic lymphohistiocytosis
Pathophysiology
Treatment
References
Familial Hemophagocytic Lymphohistiocytosis
Key points
Introduction
Incidence
Familial hemophagocytic lymphohistiocytosis subtypes
Diagnostic work-up
Treatment
Initial therapy for familial hemophagocytic lymphohistiocytosis
Hematopoietic cell transplantation
Summary/future directions
References
Hemophagocytic Lymphohistiocytosis in Adults
Key points
Introduction
Acquired hemophagocytic lymphohistiocytosis
Future directions
References
Macrophage Activation Syndrome
Key points
Introduction
History, nomenclature, and classification
Epidemiology
Pathogenesis
Clinical, laboratory, and histopathologic features
Triggering factors
Diagnostic guidelines
The new classification criteria
Management
References
The Role of Hematopoietic Stem Cell Transplantation in Treatment of Hemophagocytic Lymphohistiocytosis
Key points
Introduction
Achieving remission in pediatric hemophagocytic lymphohistiocytosis
Rationale for allogeneic hematopoietic stem cell transplantation in pediatric hemophagocytic lymphohistiocytosis
Advances in conditioning intensity
Use of alternative donor sources
Specific role of alemtuzumab and import of post-hematopoietic stem cell transplantation chimerism
Algorithm for hematopoietic stem cell transplantation familial versus infection-associated hemophagocytic lymphohistiocytosis
Unique aspects of adult-onset hemophagocytic lymphohistiocytosis
Rationale for allogeneic hematopoietic stem cell transplantation in adult hemophagocytic lymphohistiocytosis
Lack of a clear algorithm in adult-onset hemophagocytic lymphohistiocytosis
Summary
References
Index
Copyright
ELSEVIER
1600 John F. Kennedy Boulevard Suite 1800 Philadelphia, Pennsylvania, 19103-2899
http://www.theclinics.com
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA Volume 29, Number 5
October 2015 ISSN 0889-8588, ISBN 13: 978-0-323-40088-6
Editor: Jennifer Flynn-Briggs
Developmental Editor: Kristen Helm
2015 Elsevier Inc. All rights reserved.
This periodical and the individual contributions contained in it are protected under copyright by Elsevier, and the following terms and conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ([phone] (UK)/([phone] (USA).
Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions ).
Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this periodical, including any article or part of an article (please consult www.elsevier.com/permissions ). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Hematology/Oncology Clinics (ISSN 0889-8588) is published bimonthly by Elsevier Inc., 360 Park Avenue South, NewYork, NY10010-1710. Months of issue are February, April, June, August, October, and December. Business and Editorial Offices: 1600 John F. Kennedy Blvd., Ste. 1800, Philadelphia, PA 19103-2899. Customer Service Office: 3251 Riverport Lane, Maryland Heights, MO63043. Periodicals postage paid at New York, NY and at additional mailing offices. Subscription prices are $385.00 per year (domestic individuals), $633.00 per year (domestic institutions), $190.00 per year (domestic students/residents), $440.00 per year (Canadian individuals), $783.00 per year (Canadian institutions) $520.00 per year (international individuals), $783.00 per year (international institutions), and $255.00 per year (international and Canadian students/residents). International air speed delivery is included in all Clinics subscription prices. All prices are subject to change without notice. POSTMASTER: Send address changes to Hematology/Oncology Clinics of North America , Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Customer Service (orders, claims, online, change of address): Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Tel: [phone] (U.S. and Canada); 314-447-8871 (outside U.S. and Canada). Fax: [phone]. E-mail: [e-mail] (for print support) ; [e-mail] (for online support) .
Reprints. For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, New York 10010-1710; Tel.: [phone], Fax: [phone], E-mail: [e-mail] .
Hematology/Oncology Clinics of North America is covered in MEDLINE/PubMed (Index Medicus), EMBASE/Excerpta Medica, and BIOSIS.
Printed in the United States of America.
Contributors
Consulting Editors
GEORGE P. CANELLOS, MD , William Rosenberg Professor of Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
H. FRANKLIN BU